InsiderTrades.com logo

RENB Insider Trading

Insider Ownership Percentage: 21.72%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $480,575.22

Renovaro Insider Trading History Chart

This chart shows the insider buying and selling history at Renovaro by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Renovaro Share Price & Price History

Current Price: $0.35
Price Change: ▼ Price Decrease of -0.0074 (-2.06%)
As of 04/17/2025 05:00 PM ET

This chart shows the closing price history over time for RENB up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Renovaro Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/29/2024Anderson Wittekind WilliamMajor ShareholderSell1,114$1.30$1,448.20840,319View SEC Filing Icon  
7/17/2024Anderson Wittekind WilliamMajor ShareholderSell16,362$1.46$23,888.52841,433View SEC Filing Icon  
7/15/2024Anderson Wittekind WilliamMajor ShareholderSell21,954$1.41$30,955.14875,795View SEC Filing Icon  
7/11/2024Anderson Wittekind WilliamMajor ShareholderSell14,896$1.51$22,492.96897,749View SEC Filing Icon  
7/9/2024Anderson Wittekind WilliamMajor ShareholderSell4,630$1.53$7,083.90969,645View SEC Filing Icon  
7/5/2024Anderson Wittekind WilliamMajor ShareholderSell60,000$1.55$93,000.00974,275View SEC Filing Icon  
7/3/2024Anderson Wittekind WilliamMajor ShareholderSell50,000$1.51$75,500.001,034,275View SEC Filing Icon  
7/1/2024Anderson Wittekind WilliamMajor ShareholderSell60,000$1.56$93,600.001,118,828View SEC Filing Icon  
6/27/2024Anderson Wittekind WilliamMajor ShareholderSell14,671$1.50$22,006.501,178,828View SEC Filing Icon  
6/25/2024Anderson Wittekind WilliamMajor ShareholderSell20,000$1.58$31,600.001,243,499View SEC Filing Icon  
6/14/2024Anderson Wittekind WilliamMajor ShareholderSell50,000$1.58$79,000.001,263,499View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Renovaro (NASDAQ:RENB)

71.41% of Renovaro stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at RENB by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Renovaro Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/17/2025ProShare Advisors LLC32,570$27K0.0%N/A0.021%Search for SEC Filing on Google Icon
2/17/2025Nuveen Asset Management LLC151,681$0.13M0.0%+128.8%0.096%Search for SEC Filing on Google Icon
2/17/2025MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.64,923$54K0.0%+174.8%0.041%Search for SEC Filing on Google Icon
2/17/2025Deutsche Bank AG127,437$0.11M0.0%N/A0.080%Search for SEC Filing on Google Icon
2/17/2025Cantor Fitzgerald L. P.300,000$0.25M0.0%+200.0%0.189%Search for SEC Filing on Google Icon
2/14/2025Northern Trust Corp889,357$0.74M0.0%+49.5%0.560%Search for SEC Filing on Google Icon
2/14/2025The Manufacturers Life Insurance Company 45,797$38K0.0%N/A0.029%Search for SEC Filing on Google Icon
2/14/2025Voya Investment Management LLC35,312$30K0.0%N/A0.022%Search for SEC Filing on Google Icon
2/14/2025Price T Rowe Associates Inc. MD45,198$38K0.0%+183.5%0.028%Search for SEC Filing on Google Icon
2/14/2025MetLife Investment Management LLC75,454$63K0.0%N/A0.048%Search for SEC Filing on Google Icon
2/13/2025Barclays PLC179,844$0.15M0.0%+158.7%0.113%Search for SEC Filing on Google Icon
2/13/2025Wells Fargo & Company MN59,101$49K0.0%+224.9%0.037%Search for SEC Filing on Google Icon
2/12/2025Geode Capital Management LLC2,332,634$1.95M0.0%+48.4%1.470%Search for SEC Filing on Google Icon
2/12/2025JPMorgan Chase & Co.353,833$0.30M0.0%+280.4%0.223%Search for SEC Filing on Google Icon
2/11/2025Corebridge Financial Inc.57,495$48K0.0%+114.8%0.036%Search for SEC Filing on Google Icon
2/6/2025Charles Schwab Investment Management Inc.362,126$0.30M0.0%+82.0%0.228%Search for SEC Filing on Google Icon
2/4/2025Bank of New York Mellon Corp223,915$0.19M0.0%+137.2%0.141%Search for SEC Filing on Google Icon
1/31/2025New York State Common Retirement Fund52,500$44K0.0%-21.3%0.033%Search for SEC Filing on Google Icon
1/30/2025Rhumbline Advisers112,960$94K0.0%+122.6%0.071%Search for SEC Filing on Google Icon
1/17/2025SG Americas Securities LLC51,725$43K0.0%+193.3%0.033%Search for SEC Filing on Google Icon
12/26/2024JPMorgan Chase & Co.93,010$45K0.0%+347.6%0.059%Search for SEC Filing on Google Icon
11/19/2024Barclays PLC69,531$34K0.0%+315.7%0.044%Search for SEC Filing on Google Icon
11/16/2024Geode Capital Management LLC1,572,290$0.76M0.0%-9.0%0.972%Search for SEC Filing on Google Icon
11/15/2024Barclays PLC69,531$34K0.0%+315.7%0.043%Search for SEC Filing on Google Icon
11/15/2024State Street Corp1,323,832$0.64M0.0%+3.8%0.819%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers45,197$79K0.0%N/A0.031%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp125,461$0.22M0.0%N/A0.085%Search for SEC Filing on Google Icon
5/17/2024Tidal Investments LLC36,972$98K0.0%N/A0.026%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.3,916,672$10.38M0.0%+904.0%2.726%Search for SEC Filing on Google Icon
5/7/2024SG Americas Securities LLC17,263$46K0.0%N/A0.012%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Renovaro logo
Renovaro Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.
Read More on Renovaro

Today's Range

Now: $0.35
Low: $0.34
High: $0.37

50 Day Range

MA: $0.68
Low: $0.35
High: $1.19

52 Week Range

Now: $0.35
Low: $0.32
High: $2.38

Volume

390,482 shs

Average Volume

927,040 shs

Market Capitalization

$55.96 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.59

Who are the company insiders with the largest holdings of Renovaro?

Renovaro's top insider investors include:
  1. Anderson Wittekind William (Major Shareholder)
Learn More about top insider investors at Renovaro.